NovaVive Inc. Summarizes Canine Cancer Data Presented at World Veterinary Cancer Congress

31 May 2016

Belleville, Ontario – NovaVive Inc., a Canadian immunobiology company, today announced the results of studies that were presented at the 3rd World Veterinary Cancer Congress (WVCC) last week in Brazil.

The Company’s mycobacterium cell wall fraction (MCWF) technology has been developed as an intratumoral product for canine mammary cancer (Immunocidin®) and is registered for sale in the U.S. and Canada. The WVCC presentations were conducted with current formulations of MCWF as well as formulations in development:

Dr. Aleksandar Masic, Director of Product Development at NovaVive Inc., presented the results of a study using a novel MCW formulation. The study was focused on ameliorating neutropenia, a condition that results in low neutrophil counts following chemotherapy treatment in cancer patients and increases the risk of infection. The study involved 50 dogs divided into five experimental groups. All dogs received IV chemotherapy and, upon diagnosis of neutropenia (low neutrophil count), each dog was randomly allocated to one of the five groups, with four groups receiving MCW-DNA by IV within 24 hours at varying doses. The efficacy of MCW-DNA in ameliorating neutropenia was determined by comparing the duration of neutropenia in the control group versus the four MCW-DNA treatment groups. There was a clear dose response observed in the time to recovery from neutropenia.

Dr. Lucas Rodrigues, Clinical Director at Estima Veterinary Hospital (Brazil), presented the results of a study evaluating the ability of an MCWF formulation to induce serum cytokine synthesis after a single IV treatment in dogs with a variety of solid tumors. Canine-specific cytokines were measured following treatment. Two hours following treatment, a transient decrease of IL-2, IL-6, and TNF-a was observed in all dogs. At the same time, levels of IL-10 were continuously rising, and were statistically significant compared to pre-treatment.IL-10 is a multifunctional cytokine with ability to inhibit T-helper (Th1) activity, stimulate natural killer cells, inhibit tumor-induced angiogenesis and enhance the production of Nitric Oxide, which leads to tumor regression.

“The ability to ameliorate neutropenia or reduce its incidence and severity following chemotherapy treatment has significant importance from a clinical standpoint,” said Dr. Masic. “MCW-DNA administration would enable continuous use of standard of care chemotherapy-based protocols without treatment interruption or dose reduction, thus increasing efficacy and decreasing overall cost.”

The Company previously announced that its canine cancer development plan includes hemangiosarcoma, chemotherapy-induced neutropenia, and palliation as new indications for proprietary formulations of MCWF.

About NovaVive Inc.

NovaVive is a private company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with four regulator-approved products. The MCWF platform was formerly part of Bioniche Animal Health.

NovaVive also acquired the global license to MCNA for treating animal cancers. MCNA is an advanced formulation of mycobacterium cell walls and nucleic acids formulated for human applications. MCNA has been advanced through Phase III in the treatment of human bladder cancer by Bioniche Life Sciences (now Telesta Therapeutics).


For more information about the Company, please visit www.NovaVive.ca or contact:

Graeme McRae, President
Graeme.McRae@NovaVive.ca
Phone: 613-391-3837

or

Jennifer Shea, Vice-President, Investor Relations & Business Development
Jennifer.Shea@NovaVive.ca
Phone: 613-391-2097

Sign up to stay up-to-date with NovaVive news.